Biolexis News.
Biolexis Therapeutics VP of Clinical Development Selected for Dual Featured Presentations at the 2nd Innovation in Obesity Therapeutics Summit
Read more →Biolexis Therapeutics to Present Groundbreaking Data on First-in-Class Dual-Mechanism Oral Therapy for Obesity at ObesityWeek® 2025
Read more →Biolexis Therapeutics Initiates First-in-Human Clinical Trials for Novel, Oral Muscle-Sparing, Weight Loss and Type 2 Diabetes Therapies
Read more →Biolexis Therapeutics Advances Breakthrough GLP-1 and AMPK Programs into First-in-Human Clinical Trials
Read more →Biolexis Therapeutics Announces Positive Results from Expanded Diet Induced Obesity (DIO) Model Study for BLX-7006
Read more →Biolexis Therapeutics Completes Promising Pre-Clinical Studies on Novel Isoform-Specific AMPK Agonists for Weight Loss Treatment
Read more →Biolexis Unveils Promising Data with an Oral Weight Loss Drug: BLX-7006 Shows Significant Results in Preclinical Studies
Read more →The work has begun. Join us.